Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin

Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of an...

Full description

Bibliographic Details
Main Author:	Andrew Ahmann
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2015-11-01
Series:	Drugs in Context
Subjects:	type 2 diabetes mellitus sodium glucose cotransporter 2 empagliflozin blood glucose body weight insulin combination therapy hypoglycemic agents
Online Access:	http://www.drugsincontext.com/combination-therapy-in-type-2-diabetes-mellitus-adding-empagliflozin-to-basal-insulin/

Similar Items

Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review
by: Sopak Supakul, et al.
Published: (2022-06-01)

Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
by: Jun Sung Moon, et al.
Published: (2023-01-01)

Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01)

Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
by: Sungjin Chung, et al.
Published: (2019-03-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report
by: Chie Kitahara, et al.
Published: (2021-04-01)

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023-07-01)

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
by: Yimin Tu, et al.
Published: (2022-12-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020
by: Yudai Uehira, et al.
Published: (2022-06-01)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
by: Ito H, et al.
Published: (2019-09-01)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
by: Genlong Xue, et al.
Published: (2022-10-01)

Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
by: Jaehyun Lim, et al.
Published: (2024-02-01)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
by: Kosuke Mozawa, et al.
Published: (2021-10-01)

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
by: Yihai Liu, et al.
Published: (2021-01-01)

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
by: Simke W. Waijer, et al.
Published: (2020-09-01)

SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis
by: Muhammad Nadeem Ahmed Khan, et al.
Published: (2023-12-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
by: Kohei Kaku, et al.
Published: (2020-05-01)

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
by: K M Prasanna Kumar, et al.
Published: (2017-01-01)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
by: Nguyen Ngoc Trang, et al.
Published: (2021-01-01)

Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
by: Chang Chu, et al.
Published: (2022-09-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)
by: Hiroki Nakajima, et al.
Published: (2018-03-01)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
by: Munir KM, et al.
Published: (2016-04-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea
by: Pegah Mohaghegh, et al.
Published: (2023-10-01)

Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study
by: Ahmed Hassoun, et al.
Published: (2022-01-01)

Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study
by: Kenta Okada, et al.
Published: (2021-04-01)

Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
by: Sheng‐Nan Chang, et al.
Published: (2023-05-01)

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials
by: Feifei Zhou, et al.
Published: (2022-09-01)

The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
by: Wael Abu Dayyih, et al.
Published: (2024-03-01)

Short-Term Effect of Sodium Glucose Co – Transporter 2 Inhibitors on Routine Laboratory Examinations
by: Osman İnan, et al.
Published: (2022-07-01)

SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DURING THE MONTH OF RAMADAN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A TERTIARY CARE CENTRE IN KARACHI, PAKISTAN
by: Aisha Sheikh, et al.
Published: (2021-11-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
by: Yao Hao Teo, et al.
Published: (2021-03-01)

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
by: Atsushi Tanaka, et al.
Published: (2017-04-01)